The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.

Hau C Kwaan, Elizabeth H Cull

Journal: Best practice & research. Clinical haematology 2015;27(1):11-8

PMID: 24907013

Full Text on Elsevier Science View on PubMed

Abstract

Coagulopathy is a unique component of the pathology of acute promyelocytic leukaemia (APL). Though many causative factors have been elucidated, therapies to rectify the coagulopathy are far from being realised. Thrombotic and bleeding complications remain the major causes of early deaths. In this chapter, the known causes of abnormalities in haemostatic function, namely the coagulopathy and changes in the fibrinolytic system, will be reviewed. Major risk factors for these complications are identified. Current available measures for correction of the coagulopathy and their effectiveness are critically examined. Unless the coagulopathy can be effectively controlled, bleeding complications will remain an obstacle to achieving a cure for this disease. The issues that need to be addressed in next phase of investigations are also discussed.

Address: Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, and Robert H. Lurie Comprehensive Cancer Center, Olson Pavilion, 710 N.Fairbanks Court, Chicago, IL 60611, USA. Electronic address: [email protected].; Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, and Robert H. Lurie Comprehensive Cancer Center, Olson Pavilion, 710 N.Fairbanks Court, Chicago, IL 60611, USA.

DOI: 10.1016/j.beha.2014.04.005